Fed Governor Adriana Kugler to resign
Twist Bioscience Corporation (NASDAQ:TWST), a synthetic DNA specialist with a market capitalization of $2.8 billion, recently held its Annual Meeting of Stockholders, resulting in significant corporate changes. According to InvestingPro data, the company’s stock has shown notable momentum with a 27% return over the past year, despite its volatile nature. On Monday, the stockholders approved an increase in authorized common stock by an additional 100 million shares and amendments to the company’s equity incentive plan. Additionally, the Charter was amended to provide for the exculpation of certain officers from liability under specific circumstances.
The amendments to the 2018 Equity Incentive Plan, which were previously detailed in a definitive proxy statement on January 6, 2025, include an increase of 3.7 million shares reserved for issuance and the removal of the "evergreen" provision among other changes. These amendments aim to provide more flexibility in compensating and incentivizing employees. InvestingPro analysis indicates that while the company maintains strong liquidity with a current ratio of 4.96, it operates with moderate debt levels and faces profitability challenges.
Moreover, the Charter’s amendment to increase the authorized common stock and the provision for officer exculpation were effective upon the filing of a Certificate of Amendment with the Secretary of State of Delaware on February 10, 2025.
During the Annual Meeting, stockholders also voted on several other proposals, including the election of three directors, the approval of executive compensation, and the ratification of Ernst & Young LLP as the independent registered accounting firm for the fiscal year ending September 30, 2025.
The elected directors are Nelson C. Chan, Robert Ragusa, and Melissa A. Starovasnik, Ph.D., who will serve as Class I Directors for the next three years. The advisory vote on executive compensation passed, reflecting shareholder support for the company’s NEOs’ pay structures.
Twist Bioscience’s decision to expand its share capital and amend its Charter reflects its growth strategy and commitment to aligning the interests of its employees with those of its shareholders. The company has demonstrated strong revenue growth of 26% in the last twelve months, though InvestingPro analysis suggests the stock is currently trading above its Fair Value. For deeper insights into TWST’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, which provides detailed analysis of the company’s performance metrics and future outlook.
In other recent news, Twist Bioscience has been the subject of several analyst updates. Scotiabank (TSX:BNS) has increased the company’s target to $62, maintaining a Sector Outperform rating, following the company’s impressive Q1 2025 financial results. The company’s full-year fiscal 2025 guidance was also revised upward, with expectations for total revenue growth of 19-21% year-over-year. Twist Bioscience’s strong performance is attributed to the momentum in both the SynBio and NGS segments.
Barclays (LON:BARC) also raised the target for Twist Bioscience to $58, reiterating an Overweight rating, due to the company’s growing momentum, particularly in its Express portfolio and Next-Generation Sequencing (NGS) tools. Baird maintained an Outperform rating and a $48.00 price target for Twist Bioscience, highlighting the consistent pricing premiums for the company’s Express Genes service.
TD Cowen reaffirmed its Buy rating and a price target of $58.00, highlighting Twist Bioscience’s solid financial guidance for fiscal year 2025. Lastly, following a strong FY24 performance, Scotiabank raised its price target for Twist Bioscience to $54 from the previous target of $50. These are the recent developments for Twist Bioscience, shedding light on the company’s financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.